Solara Active Pharma Sciences Limited has informed the Exchange regarding Change in Auditors of the company.
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Solara Active Pharma Sciences reported its FY25 audited results on May 15, 2025. Consolidated revenue from operations stood at Rs. 1,283.76 Crores (vs Rs. 1,288.92 Cr in FY24), with a net loss of Rs. 255.45 Crores for the year — a significant improvement from a Rs. 566.96 Crore loss in FY24, helped by a lower exceptional loss of Rs. 122.18 Crores vs Rs. 190.17 Crores. Q4 FY25 standalone showed a loss of Rs. 2.10 Crores vs Rs. 166.66 Crores in the year-ago quarter. Statutory auditors Deloitte Haskins & Sells LLP issued an unmodified opinion. The board also approved allotment of 1,00,000 equity shares at Rs. 252 per share under ESOP 2018, raising Rs. 2.52 Crores. Company Secretary Mr. S. Murali Krishna retired (citing no material reasons) and was replaced by Ms. Pooja Jaya Kumar. Additionally, Grant Thornton Bharat LLP was appointed as Internal Auditor, K. Suryanarayanan re-appointed as Cost Auditor, and Ms. Parimala Natarajan appointed as Secretarial Auditor for five years (FY26–FY30).
Despite the reduced loss, the company remains in the red on a full-year basis with another exceptional charge weighing on earnings — shareholders should monitor the nature of these recurring exceptional items. The KMP retirement and new auditor appointments are routine governance changes and unlikely to affect the stock price materially. The ESOP-related share issuance is a small (~0.2%) dilution.